Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Conley

Interventional Cardiology Buffalo, NY Medical Doctor

NPI 1083611982 CMS profile 321625

100 High St, 6Th Floor, Buffalo, NY 14203

Open in the dashboard

General payments

$10,204

659 records reported · program years 2019–2025

Research payments

$19

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Conley of Buffalo, NY is reported in the CMS Open Payments database as having received $10,204 across 659 general payments and $19 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,066 67
2024 General $1,612 74
2023 General $1,641 82
2023 Research $19 1
2022 General $1,480 87
2021 General $1,157 120
2020 General $1,063 98
2019 General $2,186 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Conley
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to James Conley were reported at $1,066. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year James Conley Interventional Cardiology median Middle half National median
2019 $2,186 $1,097 $329–$3,048 $163
2020 $1,063 $473 $161–$1,480 $114
2021 $1,157 $677 $233–$1,827 $132
2022 $1,480 $978 $333–$2,724 $149
2023 $1,641 $1,136 $382–$2,986 $160
2024 $1,612 $1,181 $395–$3,326 $164
2025 $1,066 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,226 186 payments
  2. Boston Scientific Corporation $1,758 76 payments
  3. Abiomed $1,626 163 payments
  4. Medtronic Vascular, Inc. $578 66 payments
  5. Amgen Inc. $525 31 payments
  6. Abbott Laboratories $443 19 payments
  7. Philips Electronics North America Corporation $422 15 payments
  8. Edwards Lifesciences Corporation $309 8 payments
  9. Cardiovascular Systems Inc. $296 11 payments
  10. Novartis Pharmaceuticals Corporation $292 13 payments
  11. Other $1,729 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,204 659 payments
Products named General payments · program years 2019–2025
  1. Impella $1,403 159 payments
  2. ONYX FRONTIER $557 49 payments
  3. Resolute Stents $504 55 payments
  4. RESOLUTE ONYX $461 32 payments
  5. Repatha $451 27 payments
  6. Resolute Stents $441 53 payments
  7. SYMPLICITY G3 $424 32 payments
  8. WATCHMAN $382 13 payments
  9. ROTABLATOR $377 13 payments
  10. LEQVIO $275 12 payments
  11. Other $4,819 215 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $19 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

560

Median for Interventional Cardiology: 2,236

Drug cost

$96,351

Median for Interventional Cardiology: $380,412

Branded share of claims

24.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 33 $47,813
Repatha Sureclick Evolocumab Brand 27 $26,363
Jardiance Empagliflozin Brand 16 $13,446
Ezetimibe Generic 118 $2,875
Rosuvastatin Calcium Generic 81 $1,879
Metoprolol Succinate Generic 62 $1,200
Atorvastatin Calcium Generic 26 $516
Clopidogrel Clopidogrel Bisulfate Brand 31 $486
Nifedipine Er Nifedipine Brand 21 $383
Furosemide Generic 24 $256

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$50,920

Medicare's payments for the services billed

Medicare patients

344

Average age 76

Services billed

792

123 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 53%
Diabetes 42%
Chronic kidney disease 37%
Atrial fibrillation 32%
COPD 28%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $155
$155 — —
Repatha
  • Amgen Inc. $53
$53 27 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $52
$52 — —
VYNDAQEL
  • PFIZER INC. $46
$46 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

660 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record